Literature DB >> 31846027

Evaluating the consistency of large-scale pharmacogenomic studies.

Raziur Rahman1, Saugato Rahman Dhruba1, Kevin Matlock1, Carlos De-Niz1, Souparno Ghosh2, Ranadip Pal1,2.   

Abstract

Recent years have seen an increase in the availability of pharmacogenomic databases such as Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) that provide genomic and functional characterization information for multiple cell lines. Studies have alluded to the fact that specific characterizations may be inconsistent between different databases. Analysis of the potential discrepancies in the different databases is highly significant, as these sources are frequently used to analyze and validate methodologies for personalized cancer therapies. In this article, we review the recent developments in investigating the correspondence between different pharmacogenomics databases and discuss the potential factors that require attention when incorporating these sources in any modeling analysis. Furthermore, we explored the consistency among these databases using copulas that can capture nonlinear dependencies between two sets of data.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  copulas; database dependencies; pairwise relationships; pharmacogenomic databases

Year:  2019        PMID: 31846027      PMCID: PMC6917220          DOI: 10.1093/bib/bby046

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  97 in total

1.  Systematic variation in gene expression patterns in human cancer cell lines.

Authors:  D T Ross; U Scherf; M B Eisen; C M Perou; C Rees; P Spellman; V Iyer; S S Jeffrey; M Van de Rijn; M Waltham; A Pergamenschikov; J C Lee; D Lashkari; D Shalon; T G Myers; J N Weinstein; D Botstein; P O Brown
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  The Santa Cruz Workshop--May 1985.

Authors:  R L Sinsheimer
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Safikhani et al. reply.

Authors:  Zhaleh Safikhani; Nehme El-Hachem; Petr Smirnov; Mark Freeman; Anna Goldenberg; Nicolai J Birkbak; Andrew H Beck; Hugo J W L Aerts; John Quackenbush; Benjamin Haibe-Kains
Journal:  Nature       Date:  2016-11-30       Impact factor: 49.962

4.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Authors:  Tea Pemovska; Mika Kontro; Bhagwan Yadav; Henrik Edgren; Samuli Eldfors; Agnieszka Szwajda; Henrikki Almusa; Maxim M Bespalov; Pekka Ellonen; Erkki Elonen; Bjørn T Gjertsen; Riikka Karjalainen; Evgeny Kulesskiy; Sonja Lagström; Anna Lehto; Maija Lepistö; Tuija Lundán; Muntasir Mamun Majumder; Jesus M Lopez Marti; Pirkko Mattila; Astrid Murumägi; Satu Mustjoki; Aino Palva; Alun Parsons; Tero Pirttinen; Maria E Rämet; Minna Suvela; Laura Turunen; Imre Västrik; Maija Wolf; Jonathan Knowles; Tero Aittokallio; Caroline A Heckman; Kimmo Porkka; Olli Kallioniemi; Krister Wennerberg
Journal:  Cancer Discov       Date:  2013-09-20       Impact factor: 39.397

5.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

6.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Authors:  Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

7.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

8.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

9.  Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.

Authors:  Kuan-Fu Ding; Darren Finlay; Hongwei Yin; William P D Hendricks; Chris Sereduk; Jeffrey Kiefer; Aleksandar Sekulic; Patricia M LoRusso; Kristiina Vuori; Jeffrey M Trent; Nicholas J Schork
Journal:  Oncotarget       Date:  2017-04-25

10.  A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction.

Authors:  Saad Haider; Raziur Rahman; Souparno Ghosh; Ranadip Pal
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

View more
  3 in total

1.  NeRD: a multichannel neural network to predict cellular response of drugs by integrating multidimensional data.

Authors:  Xiaoxiao Cheng; Chong Dai; Yuqi Wen; Xiaoqi Wang; Xiaochen Bo; Song He; Shaoliang Peng
Journal:  BMC Med       Date:  2022-10-17       Impact factor: 11.150

2.  A cross-study analysis of drug response prediction in cancer cell lines.

Authors:  Fangfang Xia; Jonathan Allen; Prasanna Balaprakash; Thomas Brettin; Cristina Garcia-Cardona; Austin Clyde; Judith Cohn; James Doroshow; Xiaotian Duan; Veronika Dubinkina; Yvonne Evrard; Ya Ju Fan; Jason Gans; Stewart He; Pinyi Lu; Sergei Maslov; Alexander Partin; Maulik Shukla; Eric Stahlberg; Justin M Wozniak; Hyunseung Yoo; George Zaki; Yitan Zhu; Rick Stevens
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

3.  The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients.

Authors:  Zicheng Wang; Jiayi Li; Peizhi Zhang; Leizuo Zhao; Bingyin Huang; Yingkun Xu; Guangzhen Wu; Qinghua Xia
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.